Infectious disease Archives

Opinion 24 Mar 2023

PAN-TB regimens to address growing TB drug resistance

By Dr. Charles Wells, head of therapeutics development at Gates Medical Research Institute As nearly one-quarter of the world’s population is presumed to be infected with Mycobacterium tuberculosis bacteria and are at risk for developing active tuberculosis (TB), the disease represents a major public health challenge globally. As reported by the World Health Organization (WHO), […]

March 24, 2023 - 5 minutesmins - By External Contributor

News and Trends 9 Mar 2023

Researchers develop treatment for vancomycin-resistant bacteria

Researchers from several institutions have developed a treatment for bacteria resistant to vancomycin, which is also known as vancomycin-resistant Enterococcus faecalis (VRE). The group consists of researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with Singapore Centre for […]

March 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Mar 2023

Beyond Biotech podcast 37: Natural killer cells, biopharma revenue, toxic shock syndrome vaccine

This week our guests are Marit Inngjerdingen from the Institute of Clinical Medicine in Norway; Kyle Forcier, senior director of life sciences product marketing at Model N; and Dr. Andreas Roetzer, head of R&D for vaccines at Biomedical Research & Bio-Products. The next breakthrough in cancer treatment? In our body, we have an innate immune […]

March 9, 2023

News and Trends 16 Feb 2023

Lipid fingerprint could help TB treatment

A new method that measures the amounts of drugs and lipids in individual cells could help health professionals target more effective treatments for diseases such as tuberculosis (TB). Researchers from the University of Surrey in the U.K. were able to isolate individual living cells that contained drugs commonly used to treat tuberculosis and found that […]

February 16, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

First toxic shock syndrome vaccine phase 2 study completed

The first vaccine to potentially prevent Staphylococcal-induced toxic shock syndrome (TSS) has successfully completed a phase 2 study. TSS is a life-threatening condition caused by toxins that can lead to multiple organ failure and death. Nosocomial pathogen methicillin-resistant Staphylococcus aureus (MRSA) bacteria are resistant to widely-used antibiotics. Infections with MRSA are harder to treat and […]

February 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

AAHI bags $9.9M to develop nasal spray influenza RNA vaccine

The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) […]

February 7, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Jan 2023

Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation

Infex Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted qualified infectious disease product (QIDP) designation to MET-X, the company’s broad spectrum metallo-beta-lactamase (MBL) inhibitor. Infex Therapeutics’ MET-X is a resistance bypass treatment that targets Gram-negative Enterobacterales. These pathogens produce MBL enzymes to deactivate beta-lactam antibiotics and evade antibiotic clearance of […]

January 4, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Blacksmith Medicines merging with Forge Therapeutics

Blacksmith Medicines, Inc., and Forge Therapeutics have signed a definitive merger agreement. This will create a biopharma company dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes. The initial focus will be on oncology and infection. “We are excited to unveil the merger of Blacksmith and Forge, which we believe […]

January 3, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 20 Dec 2022

Watch: Valo Therapeutics at Bio-Europe

Valo Therapeutics Oy is a Finnish immunotherapy company developing antigen-coated oncolytic viruses and vaccine vectors as innovative immunotherapy approaches against cancer and infectious disease. The Valo Therapeutics lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed at the laboratory of Vincenzo Cerullo at the University of Helsinki in Finland. It turns oncolytic adenoviruses into targeted […]

December 20, 2022 - 1 minutemin - By Jim Cornall

News and Trends 16 Dec 2022

Swedish research center expanding to take on antimicrobial resistance

Research on antibiotic resistance will get a boost when the Center for Antibiotic Resistance Research (CARe) in Gothenburg, Sweden, expands. Bacterial resistance to antibiotics is one of the most serious global health threats. More than a million people die annually as a direct result of infections caused by resistant bacteria. Lack of effective antibiotics jeopardizes […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Providence Therapeutics’ mRNA rabies vaccine hits milestone

Providence Therapeutics Holdings Inc. says its new mRNA vaccine program for rabies post-exposure prophylaxis has achieved a preclinical proof-of-concept milestone. The candidate was developed in partnership with Everest Medicines utilizing Providence’s clinically validated mRNA technology platform. “We are pleased to demonstrate that Providence’s mRNA technology supports development of additional products that fight a number of […]

December 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

MinervaX raises €72M to develop Group B Streptococcus vaccine

MinervaX ApS, a privately held Danish biotech company developing a novel vaccine against Group B Streptococcus (GBS), has completed a €72 million ($76.5 million) financing round. The equity financing of €22 million ($23.4 million) was co-led by new investors Trill Impact Ventures and Pureos Bioventures and includes existing investors REPAIR Impact Fund (Novo Holdings), Sunstone […]

December 15, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Infectious disease

PAN-TB regimens to address growing TB drug resistance

Researchers develop treatment for vancomycin-resistant bacteria

Beyond Biotech podcast 37: Natural killer cells, biopharma revenue, toxic shock syndrome vaccine

Lipid fingerprint could help TB treatment

First toxic shock syndrome vaccine phase 2 study completed

AAHI bags $9.9M to develop nasal spray influenza RNA vaccine

Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation

Blacksmith Medicines merging with Forge Therapeutics

Watch: Valo Therapeutics at Bio-Europe

Swedish research center expanding to take on antimicrobial resistance

Providence Therapeutics’ mRNA rabies vaccine hits milestone

MinervaX raises €72M to develop Group B Streptococcus vaccine

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!